PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.27%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
11.47%
Positive gross profit growth while 3088.T is negative. John Neff would see a clear operational edge over the competitor.
16.10%
Positive EBIT growth while 3088.T is negative. John Neff might see a substantial edge in operational management.
15.53%
Operating income growth under 50% of 3088.T's 138.09%. Michael Burry would be concerned about deeper cost or sales issues.
12.54%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
12.53%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
12.53%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.38%
10Y revenue/share CAGR above 1.5x 3088.T's 19.41%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
81.38%
5Y revenue/share CAGR above 1.5x 3088.T's 19.41%. David Dodd would look for consistent product or market expansions fueling outperformance.
63.60%
3Y revenue/share CAGR above 1.5x 3088.T's 16.63%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-100.00%
Negative 10Y OCF/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-100.00%
Negative 5Y OCF/share CAGR while 3088.T is at 100.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-100.00%
Negative 3Y OCF/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
95.12%
Net income/share CAGR above 1.5x 3088.T's 27.66% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
95.12%
5Y net income/share CAGR above 1.5x 3088.T's 27.66%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
58.16%
Below 50% of 3088.T's 954.47%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
124.82%
10Y equity/share CAGR above 1.5x 3088.T's 41.96%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
124.82%
5Y equity/share CAGR above 1.5x 3088.T's 41.96%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
84.15%
3Y equity/share CAGR above 1.5x 3088.T's 33.26%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-50.00%
Cut dividends over 10 years while 3088.T stands at 5247.92%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-50.00%
Negative 5Y dividend/share CAGR while 3088.T stands at 5247.92%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
30.43%
Below 50% of 3088.T's 5693.58%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
22462.50%
AR growth well above 3088.T's 14.45%. Michael Burry fears inflated revenue or higher default risk in the near future.
4.04%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
13.63%
Asset growth above 1.5x 3088.T's 0.31%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.35%
Under 50% of 3088.T's 12.43%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
141.03%
We have some new debt while 3088.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-26.00%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.